Establishment of Vero cell RNA polymerase I-driven reverse genetics for Influenza A virus and its application for pandemic (H1N1) 2009 influenza virus vaccine production

References

1. Barrett P. N., Mundt W., Kistner O., Howard M. K. 2009; Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. Expert Rev Vaccines 8:607–618 [View Article][PubMed]
   [Google Scholar]
2. Brands R., Visser J., Medema J., Palache A. M., van Scharrenburg G. J. 1999; Influvac: a safe Madin Darby canine kidney (MDCK) cell culture-based influenza vaccine. Dev Biol Stand 98:93–100, discussion 111[PubMed]
   [Google Scholar]
3. de Wit E., Spronken M. I., Vervaet G., Rimmelzwaan G. F., Osterhaus A. D., Fouchier R. A. 2007; A reverse-genetics system for influenza A virus using T7 RNA polymerase. J Gen Virol 88:1281–1287 [View Article][PubMed]
   [Google Scholar]
4. Frazzati-Gallina N. M., Paoli R. L., Mourão-Fuches R. M., Jorge S. A., Pereira C. A. 2001; Higher production of rabies virus in serum-free medium cell cultures on microcarriers. J Biotechnol 92:67–72 [View Article][PubMed]
   [Google Scholar]
5. Hoffmann E., Neumann G., Hobom G., Webster R. G., Kawaoka Y. 2000a; “Ambisense” approach for the generation of influenza A virus: vRNA and mRNA synthesis from one template. Virology 267:310–317 [View Article][PubMed]
   [Google Scholar]
6. Hoffmann E., Neumann G., Kawaoka Y., Hobom G., Webster R. G. 2000b; A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci U S A 97:6108–6113 [View Article][PubMed]
   [Google Scholar]
7. Horimoto T., Murakami S., Muramoto Y., Yamada S., Fujii K., Kiso M., Iwatsuki-Horimoto K., Kino Y., Kawaoka Y. 2007; Enhanced growth of seed viruses for H5N1 influenza vaccines. Virology 366:23–27 [View Article][PubMed]
   [Google Scholar]
8. Itoh Y., Shinya K., Kiso M., Watanabe T., Sakoda Y., Hatta M., Muramoto Y., Tamura D., Sakai-Tagawa Y.other authors 2009; In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460:1021–1025[PubMed]
   [Google Scholar]
9. Keitel W. A., Dekker C. L., Mink C., Campbell J. D., Edwards K. M., Patel S. M., Ho D. Y., Talbot H. K., Guo K.other authors 2009; Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults. Vaccine 27:6642–6648 [View Article][PubMed]
   [Google Scholar]
10. Kistner O., Barrett P. N., Mundt W., Reiter M., Schober-Bendixen S., Dorner F. 1998; Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine 16:960–968 [View Article][PubMed]
    [Google Scholar]
11. Kistner O., Howard M. K., Spruth M., Wodal W., Brühl P., Gerencer M., Crowe B. A., Savidis-Dacho H., Livey I.other authors 2007; Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 25:6028–6036 [View Article][PubMed]
    [Google Scholar]
12. Massin P., Rodrigues P., Marasescu M., van der Werf S., Naffakh N. 2005; Cloning of the chicken RNA polymerase I promoter and use for reverse genetics of influenza A viruses in avian cells. J Virol 79:13811–13816 [View Article][PubMed]
    [Google Scholar]
13. Montagnon B. J., Fanget B., Vincent-Falquet J. C. 1984; Industrial-scale production of inactivated poliovirus vaccine prepared by culture of Vero cells on microcarrier. Rev Infect Dis 6:Suppl. 2S341–S344 [View Article][PubMed]
    [Google Scholar]
14. Murakami S., Horimoto T., Yamada S., Kakugawa S., Goto H., Kawaoka Y. 2008; Establishment of canine RNA polymerase I-driven reverse genetics for influenza A virus: its application for H5N1 vaccine production. J Virol 82:1605–1609 [View Article][PubMed]
    [Google Scholar]
15. Neumann G., Fujii K., Kino Y., Kawaoka Y. 2005; An improved reverse genetics system for influenza A virus generation and its implications for vaccine production. Proc Natl Acad Sci U S A 102:16825–16829 [View Article][PubMed]
    [Google Scholar]
16. Paule M. R., White R. J. 2000; Survey and summary: transcription by RNA polymerases I and III. Nucleic Acids Res 28:1283–1298 [View Article][PubMed]
    [Google Scholar]
17. Salomon R., Franks J., Govorkova E. A., Ilyushina N. A., Yen H. L., Hulse-Post D. J., Humberd J., Trichet M., Rehg J. E.other authors 2006; The polymerase complex genes contribute to the high virulence of the human H5N1 influenza virus isolate A/Vietnam/1203/04. J Exp Med 203:689–697 [View Article][PubMed]
    [Google Scholar]
18. Song M.-S., Oh T.-K., Pascua P. N., Moon H.-J., Lee J. H., Baek Y. H., Woo K.-J., Yoon Y., Sung M.-H.other authors 2009a; Investigation of the biological indicator for vaccine efficacy against highly pathogenic avian influenza (HPAI) H5N1 virus challenge in mice and ferrets. Vaccine 27:3145–3152 [View Article][PubMed]
    [Google Scholar]
19. Song M.-S., Pascua P. N., Lee J. H., Baek Y. H., Lee O.-J., Kim C.-J., Kim H., Webby R. J., Webster R. G., Choi Y. K. 2009b; The polymerase acidic protein gene of influenza A virus contributes to pathogenicity in a mouse model. J Virol 83:12325–12335 [View Article][PubMed]
    [Google Scholar]
20. Song M.-S., Lee J. H., Pascua P. N., Baek Y. H., Kwon H.-I., Park K. J., Choi H.-W., Shin Y.-K., Song J.-Y.other authors 2010; Evidence of human-to-swine transmission of the pandemic (H1N1) 2009 influenza virus in South Korea. J Clin Microbiol 48:3204–3211 [View Article][PubMed]
    [Google Scholar]
21. Thompson W. W., Shay D. K., Weintraub E., Brammer L., Cox N., Anderson L. J., Fukuda K. 2003; Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA (J Am Med Assoc) 289:179–186 [View Article][PubMed]
    [Google Scholar]
22. WHO 1998; Requirements for the use of animal cells as in vitro substrates for the production of biologicals. In WHO Technical Report Series vol. 878 pp. 20–53 Geneva: World Health Organization;
    [Google Scholar]
23. WHO 2005; WHO Guidance on Development of Influenza Vaccine Reference Viruses by Reverse Genetics 2005. World Health Organization http://www.who.int/vaccine_research/diseases/influenza/WHO_guidance_on_development_of_influenza_vaccine_reference_viruses_by_RG_2005_6.pdf
24. WHO 2010; H1N1 in Post-pandemic Period. World Health Organization http://www.who.int/mediacentre/news/statements/2010/h1n1_vpc_20100810/en/index.html